{
  "id": 17252217,
  "title": "Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat",
  "url": "https://urgent.news/2026/10/30/bernstein-socgen-raises-eli-lilly-stock-price-target-on-strong-q3-beat",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T16:04:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/bernstein-socgen-raises-eli-lilly-stock-price-target-on-strong-q3-beat-93CH-4988312"
  },
  "original_language": "en",
  "account": "Bernstein SocGen Group has raised its price target for Eli Lilly (NYSE: LLY) stock to $1,450.00, citing strong third-quarter performance. The firm increased its revenue expectations for Eli Lilly to $92.5 billion, which is nearly $10 billion above the company's initial guidance for 2026. The third-quarter revenue of $24.4 billion surpassed expectations by about $1.9 billion. Eli Lilly has experienced a 45.5% increase in revenue over the past year, reaching $86.5 billion, driven by robust demand for its diabetes and obesity treatments. Eight analysts have revised their earnings estimates upward for the upcoming period. The company maintains a financial health score of 3.53 out of 5. Performance margins stayed above 50% despite ongoing reinvestment efforts. The $1 billion increase in revenue was primarily due to favorable items, with the remaining portion representing underlying performance. Analysts highlight Eli Lilly's pipeline, including Reta for a Q1 2027 filing and EloraTZP in Phase 3 trials, as well as expansion into international markets and the middle-income category outside the US. The company's Innovation Day is scheduled for December 7. While the stock has delivered a 63.7% return over the past year and is near its 52-week high, InvestingPro analysis suggests it may be overvalued at current levels.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}